New combination of old drugs improves survival in patients with prostate cancer

A novel combination of well-known drugs prolongs survival in patients with hormone/castration-sensitive prostate cancer, according to late breaking research presented at the ESMO Congress 2021. The PEACE-1 and STAMPEDE studies found that the addition of abiraterone acetate plus prednisolone (AAP) to standard therapy lengthened survival compared to standard therapy alone.

source https://medicalxpress.com/news/2021-09-combination-drugs-survival-patients-prostate.html